Quick answer: A seven-residue peptide such as Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is typically made by stepwise solid-phase peptide synthesis, then cleaved from the resin, purified by reversed-phase HPLC and lyophilized. Each step leaves characteristic impurities, and the Met and His residues are the usual trouble spots. This is a general chemistry primer, not a description of any particular supplier's process. Laboratory research use only.
Why look at synthesis at all
Most Semax articles discuss biology. This one discusses chemistry, because the biology rests on the chemistry: a published effect is only reproducible if the material is what the paper's authors thought it was. Understanding how a seven-residue peptide is made explains what impurities to expect, why a purity percentage means what it does, and why storage and handling choices matter after the vial arrives.
This is a general primer on peptide synthesis applied to the Semax sequence, Met-Glu-His-Phe-Pro-Gly-Pro. It does not describe how any particular supplier makes its material; the Semax product page lists specifications (15 mg lyophilized vial, purity at least 98% by HPLC, formula C37H51N9O10S) and does not state a synthesis route. It is for laboratory readers only. For biology, see the Semax research overview and the what is Semax explainer.
The basic idea of solid-phase synthesis
In 1963 Merrifield described the synthesis of a peptide on an insoluble support, the foundation of solid-phase peptide synthesis [1]. The principle is simple. The first residue is anchored to a resin by its C-terminus. Each subsequent residue is added to the free amino end of the growing chain. After every coupling, excess reagents are washed away by filtration, which is the key convenience: no purification is needed between steps. When the chain is complete it is cleaved from the resin and its side-chain protecting groups are removed, and the crude peptide is purified. Reviews of the method describe it as the standard approach to preparing biologically relevant peptides [2].
Because assembly runs from the C-terminus to the N-terminus, Semax is built in the order Pro, Gly, Pro, Phe, His, Glu, Met. The Pro-Gly-Pro tail goes on first and the N-terminal methionine last.
The cycle, step by step
| Step | What happens | Why it matters |
|---|---|---|
| Resin loading | First residue (Pro) attached through its C-terminus | Sets the C-terminal form (free acid or amide) |
| Deprotection | The temporary N-terminal protecting group is removed | Exposes the amine for the next coupling |
| Activation and coupling | Next protected residue is activated and joined | Incomplete coupling creates deletion sequences |
| Washing | Excess reagents removed | Prevents carry-over |
| Capping (optional) | Unreacted amines blocked | Turns deletion sequences into easily separated truncations |
| Repeat | Seven residues, six more cycles after loading | Errors accumulate with length |
| Cleavage | Peptide released and side chains deprotected | Reactive species can modify sensitive residues |
| Purification | Reversed-phase HPLC | Sets the final purity |
| Lyophilization | Freeze-drying | Gives the stable powder supplied in a vial |
Residue-specific points for Semax
Proline. Proline is a secondary amine, and couplings onto it can be slower than usual. The Pro-Gly-Pro tail has two prolines, Chemists manage this through the choice of coupling reagents and conditions.
Glycine. Unhindered and easy to couple.
Phenylalanine and histidine. Histidine is the residue most associated with racemization during activation, which is why side-chain protection and gentler coupling conditions are chosen for it. A racemized histidine would give a diastereomer that may elute close to the main peak.
Glutamic acid. Its side chain is protected during assembly and deprotected at cleavage.
Methionine. The thioether is oxidation-prone, and during acid cleavage it can be oxidized or alkylated by reactive species released from protecting groups. Scavengers are included in the cleavage mixture to reduce this. After cleavage, oxidation can continue in solution, which is the basis of the storage advice in the storing research peptides guide and the reason mass spectrometry checks for a +16 species.
What the crude product contains
After cleavage the material is a mixture. The target peptide is the main component, accompanied by deletion sequences from missed couplings, truncated sequences, products of incomplete side-chain deprotection, oxidation products at methionine, diastereomers from racemization, and residual scavengers and salts. The overview literature on the sustainability of peptide synthesis and purification describes how purification and the solvents it consumes make up a large part of the effort and cost of manufacturing, which is a reminder that the purity figure on a vial is the output of a deliberate and resource-intensive step [3]. Oxidation of residues such as methionine is one of the chemical instability routes reviewed for protein drugs [4], and the stability of peptide pharmaceuticals in general is reviewed in [5].
Purification and lyophilization
Reversed-phase HPLC separates peptides by hydrophobicity. Fractions are analyzed, those containing the target at the required purity are pooled, and the solvent is removed by freeze-drying. The pooled fractions typically contain trifluoroacetic acid or another ion-pairing acid from the mobile phase, so the lyophilized peptide is a salt, and the mass in the vial includes counter-ions and some water. This is why a vial labeled 15 mg holds somewhat less than 15 mg of peptide on a strict basis, and why quantitative work sometimes calls for amino acid analysis or another content assay. It is also why the purity percentage, which concerns peptide-related species by HPLC peak area, is a different thing from peptide content by weight. The understanding HPLC purity article develops the point.
| Quantity | What it describes |
|---|---|
| HPLC purity (%) | Main peak area relative to all detected peaks |
| Peptide content (%) | Mass of peptide per mass of powder, after counter-ions and water |
| Identity | Match of measured mass and sequence to expected values |
| Net peptide per vial | Labeled mass multiplied by peptide content |
Why the sequence length helps
Seven residues is short. In solid-phase synthesis, yield and purity fall as chains grow because small per-step inefficiencies compound: if each cycle were 99% efficient, the overall fraction of correct chains after seven residues would be 0.99 to the seventh power, about 93%, while for a 40-residue chain it would be about 67%. These are illustrations of the arithmetic, not measurements for any product. The point is that short peptides like Semax are among the easier targets, and the residual challenge is concentrated in a few residues, which is why those residues are the focus of analytical checks.
What this means for a laboratory
Knowing the process tells a researcher what to look for. Ask what the HPLC method resolved, whether identity was confirmed by mass, and whether the report is lot-specific; the how to read a COA guide and the COA page explain where such documentation is published. If the work depends on the amount of intact peptide, run a content check or calibrate against a reference. Prepare stock by vial mass divided by diluent volume using the reconstitution calculator, keep stocks cold and sealed, and read the Semax purity testing article for what an analysis must show. Related reading is in the research library, and materials are listed in the shop.
Analytical checkpoints along the route
Quality is not only measured at the end. A manufacturer can test during synthesis, for example by checking for free amines after a coupling to confirm it went to completion, and can analyze the crude product by HPLC and mass spectrometry before purification to see what must be removed. After purification, individual fractions are analyzed so that only those meeting the target are pooled. The final lyophilized product is then tested for purity and identity. A laboratory seeing only the final report cannot know which of these checkpoints were used, which is one reason lot-specific documentation with a stated method is more informative than a generic statement.
For Semax, the final identity test is conceptually simple: the measured mass should match the calculated value within instrument tolerance, and the chromatogram should show a dominant peak with minor peaks that are small and, ideally, explained. If a minor peak sits about 16 mass units above the main species it is probably the methionine sulfoxide; a peak at lower mass could be a deletion product. Interpreting such peaks requires the method details, which is again why the method should be stated on the report.
Terms used in peptide synthesis
| Term | Meaning |
|---|---|
| Resin | Insoluble polymer support to which the chain is anchored |
| Protecting group | Temporary or permanent blocker on an amine or side chain |
| Coupling | Formation of the peptide bond between residues |
| Deletion sequence | Chain missing one residue due to a failed coupling |
| Racemization | Loss of stereochemical purity at a residue, giving a diastereomer |
| Scavenger | Additive in cleavage that traps reactive species |
| Counter-ion | Ion paired with the peptide in the lyophilized salt |
Limits of this primer
It describes general practice, not a validated process for any product. Real manufacturing involves choices of resin, protecting-group strategy, coupling reagents and purification gradients that are not discussed here. It makes no statement about any supplier's method, and it offers nothing about use outside a laboratory.
Frequently asked questions
How is a short peptide like Semax usually made?
By stepwise solid-phase peptide synthesis from C-terminus to N-terminus, followed by cleavage, reversed-phase HPLC purification and lyophilization.
In what order are the residues added?
Pro, Gly, Pro, Phe, His, Glu and finally Met, since assembly runs from the C-terminus.
Who introduced solid-phase synthesis?
Merrifield, in a 1963 paper describing the synthesis of a tetrapeptide on a solid support.
Which residues are most troublesome in Semax?
Methionine, which is oxidation-prone, and histidine, which is prone to racemization during activation.
What impurities are expected?
Deletion and truncated sequences, incompletely deprotected products, oxidized methionine, diastereomers and residual salts or scavengers.
Does the product page state how the material is made?
No. It states form, purity, formula and storage, and does not describe a synthesis route.
Is HPLC purity the same as peptide content?
No. Purity is the main peak's share of detected peak area, while content is peptide mass per powder mass after counter-ions and water.
Why is a vial labeled 15 mg not exactly 15 mg of peptide?
Counter-ions and residual water are part of the powder mass, so net peptide is somewhat less than the labeled mass.
How can a lab confirm identity?
By mass spectrometry against calculated values: average mass about 813.9 g/mol and [M+H]+ near 814.36.
Is this a guide to making the peptide at home?
No. It is a conceptual primer for understanding quality documentation.
Research-use statement
This product is supplied for laboratory research use only. It is not a drug, food or cosmetic, and it is not for human or animal consumption. This article is a chemistry primer and does not recommend any application.
Related reading: Semax Cognitive Function Research: Rodent Behavior Models, Semax Gene Expression in Rat Brain: Studies Compared, Semax Intranasal Route in Preclinical Research Studies.
References
- Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J. Am. Chem. Soc.. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- Palomo JM. Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides. RSC Adv.. 2014;4(62):32658-32672. doi:10.1039/C4RA02458C
- Isidro-Llobet A, Kenworthy MN, Mukherjee S, Kopach ME, Wegner K, Gallou F, et al. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. The Journal of Organic Chemistry. 2019;84(8):4615-4628. doi:10.1021/acs.joc.8b03001
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotech & Bioengineering. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: An Update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
